Abbott India Sell Call: ROE Strong, Charts Weak FY26

What changed in the latest call

Abbott India Ltd. has been downgraded to a Sell rating by MarketsMOJO, with the shift driven more by weakening technical signals than by long-term business quality. The company continues to show strong fundamentals, including high return ratios and a debt-free balance sheet. But the update flags a pause in quarterly momentum for Q3 FY25-26, along with softer operating-efficiency indicators. The result is a risk-reward profile that looks less favourable at current prices. The stock has also underperformed broader indices over the last year, adding to investor caution.

Long-term fundamentals remain strong

On longer-term metrics, Abbott India still screens as a high-quality business. The note cites an average Return on Equity (ROE) of 34.23%, pointing to efficient capital use. Operating profit has grown at an annual rate of 17.25%, indicating steady expansion over time. The capital structure is described as conservative, with an average debt-to-equity ratio of zero. These indicators typically support premium valuations in the market. But the downgrade suggests that near-term factors are starting to weigh more heavily on sentiment.

Flat Q3 FY25-26 and working-capital signals

The company’s quarterly results for Q3 FY25-26 are described as flat, signalling a pause in growth momentum. Alongside this, operational efficiency metrics have weakened in the latest half-year view. Inventory Turnover Ratio is reported at 7.16 times, and Debtors Turnover Ratio at 13.24 times. Both are framed as slower asset turnover and potential working-capital management issues. These trends have reduced the quality grade in the assessment. The key takeaway is that the core franchise is strong, but near-term execution and efficiency are being watched more closely.

Valuation: expensive, even after a correction

Valuation remains one of the central concerns in the report. Abbott India is cited as trading at a Price to Book (P/B) ratio of 14.4 in the MarketsMOJO discussion, which is labelled very expensive versus historical norms and sector averages. The same note points to a strong ROE of 38% in the latest period as a partial justification for the premium. The Price/Earnings to Growth (PEG) ratio is stated at 2.7, against earnings growth of 14.2% over the past year, indicating high growth expectations embedded in the price. Elsewhere in the provided data, P/B is also shown at 13.23 and 15.48 in different market snapshots, reinforcing the broader point that the stock trades at elevated multiples.

Stock returns: mixed across timeframes

Over the past year, profits are reported to have risen 14.2%, but the stock price is stated to have fallen 11.74% over the same period. In comparison, the BSE500 index delivered a positive return of 7.32% over the last year, highlighting relative underperformance. Year-to-date, the stock is shown down 6.69%, while the Sensex is down 8.98% in the same period in that section, implying a smaller decline than the benchmark. Longer-term performance remains strong in the note, with a 10-year return of 450.98% versus the Sensex’s 212.84%, and a 5-year return of 84.74% versus the Sensex’s 52.01%. A separate returns table in the text also shows 1-year returns around -11.46% and 5-year returns around 84.37%, broadly consistent with the “mid-80% over five years” picture.

Technical indicators turned decisively bearish

The most direct trigger cited for the downgrade is the deterioration in technical indicators. MarketsMOJO’s technical grade is described as shifting from mildly bearish to outright bearish, signalling weaker momentum and higher selling pressure. Weekly MACD readings are bearish, while the monthly view is mildly bearish. Bollinger Bands are bearish on the weekly timeframe and mildly bearish monthly. Daily moving averages are described as bearish, confirming a near-term downtrend. KST (Know Sure Thing) is bearish weekly and mildly bearish monthly, while RSI and OBV show no clear signals.

Price levels and recent trading range

The note highlights a correction from a 52-week high of ₹35,921.55 to a current level near ₹27,125. It also reports a day’s trading range between ₹26,500.05 and ₹27,292.95, with a day change of -0.81%, reflecting cautious sentiment. In another price update, the stock is shown last trading at ₹26,530.00 versus a previous close of ₹26,355.00, a 0.67% move. These multiple snapshots indicate the stock has been volatile, with the broader trend described as weaker in the recent period.

Key numbers at a glance

Returns and index comparison (as stated)

Analyst targets and market positioning

The text also includes multiple target and recommendation snapshots from different sources. One set shows an average one-year price target of ₹36,623.10, with a low of ₹30,633.30 and a high of ₹42,000.00. Another snapshot shows an average target of ₹34,047 with a high of ₹40,128 and a low of ₹28,700, and mentions a small upside of 0.79% versus a referenced current price. Separately, CLSA is described as downgrading its stance to “outperform” from “buy” while raising its target to ₹27,500 after Q2FY24 results. These mixed signals sit alongside the MarketsMOJO Sell downgrade, underscoring how valuation and near-term momentum are influencing views.

What to monitor next

The report’s conclusion is that Abbott India’s long-term fundamentals remain solid, but current valuation and weakening technicals reduce the margin of safety. The operational metrics on inventory and receivables turnover are also positioned as near-term watchpoints. Investors tracking the stock may focus on upcoming quarterly results for signs that growth momentum is returning. Technical indicators and price behaviour around recent support zones are also likely to remain in focus. Any sustained improvement would need to be visible in both operating performance and market trend signals, as reflected in the downgrade rationale.